Ross T. Cromarty

The paper uses metabolomics to show that HIV-treated individuals have metabolic disruptions, including lipid changes and inflammation markers, despite viral suppression.

This study links microbial dysbiosis, systemic inflammation, and metabolomic disruptions to SNAE risk in treated HIV patients through multi-omic analysis.

This study identifies gut barrier integrity biomarkers linked to inflammation and disease severity in hospitalized COVID-19 patients using plasma biomarker analysis and a random forest model.

The paper shows that residual HIV production in lymph nodes of ART-suppressed individuals drives pyroptosis and is counter-regulated by GLP-1 upregulation in the ileum.

This study shows that pre-treatment gut microbiome diversity in HIV patients correlates with immune activation and reduced HIV RNA+ cells after N-803 treatment.

This study examines the impact of SARS-CoV-2 infection on intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients, finding associations between specific microbial changes and disease severity.